r Honey Heussler describes the scientific rationale underpinning the RECONNECT cannabidiol (CBD) FX clinical trial currently underway in Adelaide, Brisbane, Melbourne & Sydney. The RECONNECT study is looking to understand whether the (Zynerba) ZYGEL CBD transdermal gel product helps in some behavioural issues associated with Fragile X syndrome. Dr Honey Heussler outlined the working of the human endocannabinoid system, the impact of Fragile X syndrome on that system, and how cannabidiol (non-THC CBD) can provide regulation and control. Dr Heussler also outlined the operation and findings of the earlier clinical trial phases which have preceded Zynerba’s current RECONNECT study. The RECONNECT study remains open in Australia until 31 March 2024. Individuals with a diagnosis of Fragile X syndrome and who are aged 3-22 years old and have behavioural symptoms may be eligible to participate in the study. From our FX Research Roundup webinar July 2023.